NASDAQ:DCPHDeciphera Pharmaceuticals Stock Price, Forecast & News

Deciphera Pharmaceuticals' stock was trading at $44.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, DCPH stock has increased by 23.6% and is now trading at $54.90. View which stocks have been most impacted by Coronavirus.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Deciphera Pharmaceuticals.

Deciphera Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 7th 2020. View our earnings forecast for Deciphera Pharmaceuticals.

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) posted its quarterly earnings results on Tuesday, May, 5th. The company reported ($1.36) earnings per share for the quarter, missing analysts' consensus estimates of ($1.28) by $0.08. The company had revenue of $0.06 million for the quarter, compared to analyst estimates of $2.50 million. View Deciphera Pharmaceuticals' earnings history.

16 brokerages have issued twelve-month price objectives for Deciphera Pharmaceuticals' shares. Their forecasts range from $42.00 to $91.00. On average, they anticipate Deciphera Pharmaceuticals' share price to reach $68.31 in the next year. This suggests a possible upside of 24.4% from the stock's current price. View analysts' price targets for Deciphera Pharmaceuticals.

Media stories about DCPH stock have been trending negative recently, according to InfoTrie. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Deciphera Pharmaceuticals earned a daily sentiment score of -2.1 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Deciphera Pharmaceuticals.

Deciphera Pharmaceuticals saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 3,520,000 shares, an increase of 12.1% from the June 15th total of 3,140,000 shares. Based on an average daily volume of 517,500 shares, the days-to-cover ratio is currently 6.8 days. Currently, 9.7% of the company's stock are short sold. View Deciphera Pharmaceuticals' Current Options Chain.

Some companies that are related to Deciphera Pharmaceuticals include Catalent (CTLT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), Dr.Reddy's Laboratories (RDY), Ionis Pharmaceuticals (IONS), Mylan (MYL), ACADIA Pharmaceuticals (ACAD), Perrigo (PRGO), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), PPD (SDGR), Reata Pharmaceuticals (RETA) and United Therapeutics (UTHR). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include Ionis Pharmaceuticals (IONS), Allena Pharmaceuticals (ALNA), Viking Therapeutics (VKTX), GW Pharmaceuticals PLC- (GWPH), Immunomedics (IMMU), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), AbbVie (ABBV), Bausch Health Companies (BHC) and Cytokinetics (CYTK).

(DCPH) raised $101 million in an IPO on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DCPH stock can currently be purchased for approximately $54.90.

Deciphera Pharmaceuticals has a market capitalization of $3.07 billion and generates $25 million in revenue each year. The company earns $-192,260,000.00 in net income (profit) each year or ($4.48) on an earnings per share basis. Deciphera Pharmaceuticals employs 112 workers across the globe.

The official website for Deciphera Pharmaceuticals is www.deciphera.com.

Deciphera Pharmaceuticals' mailing address is 200 SMITH STREET, Waltham MA, 02451. The company can be reached via phone at 781-209-6400 or via email at [email protected]